Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
Table 4
Subgroup anatomical and visual measurements following aflibercept.
Baseline mean (IQR)
Final mean (IQR)
value
Persistent intraretinal fluid†
Central retinal thickness (µm)
422.29 (340.5–491.5)
300.57 (281–338)
0.018
Visual acuity (logMAR)
0.90 (0.65–1.3)
0.86 (0.51–1.02)
0.596
Total retinal fluid (mm3)
5.19 (3.34–6.63)
4.46 (2.91–5.25)
0.018
Persistent subretinal fluid‡
Central retinal thickness (µm)
379.33 (294.5–417)
309.48 (242.5–344)
<0.001
Visual acuity (logMAR)
0.47 (0.27–0.63)
0.45 (0.21–0.57)
0.692
Total retinal fluid (mm3)
4.62 (3.03–6.79)
4.25 (2.81–5.39)
0.007
Persistent multiple layer flui
Central retinal thickness (µm)
360.33 (271–425)
278 (232–307)
0.021
Visual acuity (logMAR)
0.48 (0.3–0.58)
0.48 (0.28–0.52)
0.933
Total retinal fluid (mm3)
5.40 (3.52–7.6)
4.83 (2.88–7.58)
0.008
7 patients, ‡27 patients, and 9 patients. logMAR, logarithm of minimum angle of resolution. IQR, interquartile range.
